REFERENCES

1. Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29:S32-42.

2. Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79:287-95.

3. Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:20-30.

4. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-33.

5. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.

6. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904.

7. Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461-78.

8. Sanyal AJ, Van Natta ML, Clark J, et al. ; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559-69.

9. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158:1611-25.e12.

10. Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol. 2022;76:1362-78.

11. Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21:2026-39.

12. Castéra L, Nègre I, Samii K, Buffet C. Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: a randomized placebo-controlled trial. Am J Gastroenterol. 2001;96:1553-7.

13. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.

14. Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73:1322-32.

15. Ratziu V, Charlotte F, Heurtier A, et al. ; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-906.

16. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-9.

17. Bedossa P. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289-93.

18. Kleiner DE, Brunt EM, Van Natta M, et al. ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21.

19. Bedossa P; FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565-75.

20. Wong VWS, Zelber-Sagi S, Cusi K, et al. Management of NAFLD in primary care settings. Liver Int. 2022;42:2377-89.

21. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007-19.

22. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657-69.

23. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.

24. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563-77.

25. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749-62.

26. Morin O, Vallières M, Jochems A, et al. A deep look into the future of quantitative imaging in oncology: a statement of working principles and proposal for change. Int J Radiat Oncol Biol Phys. 2018;102:1074-82.

27. Siddiqui MS, Yamada G, Vuppalanchi R, et al. ; NASH Clinical Research Network. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 2019;17:1877-85.e5.

28. Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71:371-8.

29. Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol. 2019;71:523-33.

30. Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int. 2021;41:261-70.

31. Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol. 2021;75:786-94.

32. Tayob N, Corley DA, Christie I, et al. Validation of the updated hepatocellular carcinoma early detection screening algorithm in a community-based cohort of patients with cirrhosis of multiple etiologies. Clin Gastroenterol Hepatol. 2021;19:1443-50.e6.

33. Fujii H, Fujii M, Iwaki M, et al. ; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease. Hepatol Res. 2023;53:391-400.

34. Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol. 2020;73:1023-9.

35. Balkhed W, Åberg FO, Nasr P, Ekstedt M, Kechagias S. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: a long-term follow-up study. Liver Int. 2022;42:1545-56.

36. Vali Y, Lee J, Boursier J, et al. ; LITMUS systematic review team†. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020;73:252-62.

37. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59:1245-51.

38. Saarinen K, Färkkilä M, Jula A, et al. Enhanced liver Fibrosis® test predicts liver-related outcomes in the general population. JHEP Rep. 2023;5:100765.

39. Labenz C, Arslanow A, Nguyen-Tat M, et al. Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL. J Hepatol. 2022;77:695-701.

40. Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism. 2020;111S:154320.

41. Bourganou MV, Chondrogianni ME, Kyrou I, et al. Unraveling metabolic dysfunction-associated steatotic liver disease through the use of omics technologies. Int J Mol Sci. 2025;26:1589.

42. Vitorino R. Transforming clinical research: the power of high-throughput omics integration. Proteomes. 2024;12:25.

43. Ghosh S, Zhao X, Alim M, Brudno M, Bhat M. Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment. Gut. 2025;74:295-311.

44. Sun J, Shi R, Wu Y, et al. Integration of transcriptomic analysis and multiple machine learning approaches identifies NAFLD progression-specific hub genes to reveal distinct genomic patterns and actionable targets. J Big Data. 2024;11:40.

45. Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014;61:75-81.

46. Bianco C, Jamialahmadi O, Pelusi S, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74:775-82.

47. Lan T, Tacke F. Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies. Metabolism. 2024;161:156015.

48. Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283:356-70.

49. Jamialahmadi O, Mancina RM, Ciociola E, et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology. 2021;160:1634-46.e7.

50. Baselli GA, Jamialahmadi O, Pelusi S, et al. ; EPIDEMIC Study Investigators. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol. 2022;77:596-606.

51. Abul-Husn NS, Cheng X, Li AH, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378:1096-106.

52. Walker RW, Belbin GM, Sorokin EP, et al. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol. 2020;72:1070-81.

53. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209-17.

54. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883-94.

55. Baboota RK, Rawshani A, Bonnet L, et al. BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH. Nat Metab. 2022;4:1007-21.

56. Sanyal AJ, Williams SA, Lavine JE, et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2023;78:693-703.

57. Zhu Q, Li H, Ao Z, et al. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis. J Nanobiotechnology. 2022;20:349.

58. McGlinchey AJ, Govaere O, Geng D, et al. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Rep. 2022;4:100477.

59. Perakakis N, Polyzos SA, Yazdani A, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study. Metabolism. 2019;101:154005.

60. Chen J, Lu RS, Diaz-Canestro C, et al. Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese. Comput Struct Biotechnol J. 2024;23:791-800.

61. Moolla A, de Boer J, Pavlov D, et al. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. Aliment Pharmacol Ther. 2020;51:1188-97.

62. Khusial RD, Cioffi CE, Caltharp SA, et al. Development of a plasma screening panel for pediatric nonalcoholic fatty liver disease using metabolomics. Hepatol Commun. 2019;3:1311-21.

63. Lewinska M, Santos-Laso A, Arretxe E, et al. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine. 2021;73:103661.

64. Lu H, George J, Eslam M, et al. Discriminatory changes in circulating metabolites as a predictor of hepatocellular cancer in patients with metabolic (Dysfunction) associated fatty liver disease. Liver Cancer. 2023;12:19-31.

65. De Vincentis A, Tavaglione F, Jamialahmadi O, et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol. 2022;20:658-73.

66. Eslam M, Hashem AM, Romero-Gomez M, et al. ; International Liver Disease Genetics Consortium (ILDGC). FibroGENE: a gene-based model for staging liver fibrosis. J Hepatol. 2016;64:390-8.

67. Verweij N, Haas ME, Nielsen JB, et al. Germline mutations in CIDEB and protection against liver disease. N Engl J Med. 2022;387:332-44.

68. Chen VL, Oliveri A, Miller MJ, et al. PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis. Gastroenterology. 2023;164:966-77.e17.

69. Emdin CA, Haas M, Ajmera V, et al. Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. Gastroenterology. 2021;160:1620-33.e13.

70. Grimaudo S, Pipitone RM, Pennisi G, et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18:935-44.e3.

71. Govaere O, Cockell S, Tiniakos D, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med. 2020;12:eaba4448.

72. Conway J, Pouryahya M, Gindin Y, et al. Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH. Cell Rep Med. 2023;4:101016.

73. Tobaruela-Resola AL, Milagro FI, Elorz M, et al. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment. J Physiol Biochem. 2025;81:1275-88.

74. Starmann J, Fälth M, Spindelböck W, et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One. 2012;7:e46584.

75. Bell LN, Theodorakis JL, Vuppalanchi R, et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology. 2010;51:111-20.

76. Feng G, Zhang X, Zhang L, et al. ; CHESS-MAFLD Consortium. Novel urinary protein panels for the non-invasive diagnosis of non-alcoholic fatty liver disease and fibrosis stages. Liver Int. 2023;43:1234-46.

77. Yuan X, Sun Y, Cheng Q, et al. Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease. J Proteomics. 2020;221:103683.

78. Luo Y, Wadhawan S, Greenfield A, et al. SOMAscan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH. Hepatol Commun. 2021;5:760-73.

79. Govaere O, Hasoon M, Alexander L, et al. ; LITMUS Investigators. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nat Metab. 2023;5:572-8.

80. Jiang Y, Zhuang X, Zhang J, et al. Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease. Front Endocrinol. 2023;14:1171397.

81. Rodríguez-Suárez E, Duce AM, Caballería J, et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl. 2010;4:362-71.

82. Kalhan SC, Guo L, Edmison J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism. 2011;60:404-13.

83. Li Z, Luo G, Gan C, et al. Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease. Nat Genet. 2025;57:3112-25.

84. Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB, et al. ; DBDS Genomic consortium. Multiomics study of nonalcoholic fatty liver disease. Nat Genet. 2022;54:1652-63.

85. Wood GC, Chu X, Argyropoulos G, et al. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep. 2017;7:43238.

86. Zhou Y, Orešič M, Leivonen M, et al. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites. Clin Gastroenterol Hepatol. 2016;14:1463-72.e6.

87. Oh TG, Kim SM, Caussy C, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 2020;32:878-88.e6.

88. Caussy C, Loomba R. Gut microbiome, microbial metabolites and the development of NAFLD. Nat Rev Gastroenterol Hepatol. 2018;15:719-20.

89. Quesada-Vázquez S, Castells-Nobau A, Latorre J, et al. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity. Cell Rep Med. 2023;4:101341.

90. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005;42:665-74.

91. Atabaki-Pasdar N, Ohlsson M, Viñuela A, et al. Predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Med. 2020;17:e1003149.

92. Wen W, Liu Z, Tan W, et al. Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH. NPJ Digit Med. 2026;9:167.

93. Leung H, Long X, Ni Y, et al. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med. 2022;14:eabk0855.

94. Anspach GB, Flight RM, Park S, et al. Integrated multi-omic analyses reveal novel gene-metabolite relationships in human steatohepatitic hepatocellular carcinoma. J Lipid Res. 2026;67:101081.

95. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-8.

96. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547-54.

97. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537-64.

98. Furlan A, Tublin ME, Yu L, Chopra KB, Lippello A, Behari J. Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease. AJR Am J Roentgenol. 2020;214:W20-6.

99. Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. ; NASH Clinical Research Network. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:156-63.e2.

100. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454-62.

101. Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016;65:570-8.

102. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022-30.

103. Braude M, Roberts S, Majeed A, et al. Liver stiffness (Fibroscan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. Liver Int. 2023;43:90-9.

104. Shili-Masmoudi S, Wong GL, Hiriart JB, et al. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int. 2020;40:581-9.

105. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107:1862-71.

106. Petta S, Sebastiani G, Viganò M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol. 2021;19:806-15.e5.

107. Boursier J, Hagström H, Ekstedt M, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol. 2022;76:1013-20.

108. Serra-Burriel M, Graupera I, Torán P, et al. ; investigators of the LiverScreen Consortium. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019;71:1141-51.

109. Jang JK, Lee ES, Seo JW, et al. Two-dimensional shear-wave elastography and US attenuation imaging for nonalcoholic steatohepatitis diagnosis: a cross-sectional, multicenter study. Radiology. 2022;305:118-26.

110. Lee DH, Cho EJ, Bae JS, et al. Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021;19:797-805.e7.

111. Herrmann E, de Lédinghen V, Cassinotto C, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology. 2018;67:260-72.

112. Zhou J, Yan F, Xu J, et al. Diagnosis of steatohepatitis and fibrosis in biopsy-proven nonalcoholic fatty liver diseases: including two-dimension real-time shear wave elastography and noninvasive fibrotic biomarker scores. Quant Imaging Med Surg. 2022;12:1800-14.

113. Indre MG, Leucuta DC, Lupsor-Platon M, et al. Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis. Hepatology. 2025;82:454-69.

114. Ozturk A, Mohammadi R, Pierce TT, et al. Diagnostic accuracy of shear wave elastography as a non-invasive biomarker of high-risk non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Ultrasound Med Biol. 2020;46:972-80.

115. Chen G, Yang JC, Zhang GX, Cheng Z, Du X. Evaluation of six noninvasive methods for the detection of fibrosis in chinese patients with obesity and nonalcoholic fatty liver disease. Obes Surg. 2022;32:3619-26.

116. Mendoza YP, Rodrigues SG, Delgado MG, et al. Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two-dimensional shear wave elastography in non-alcoholic fatty liver disease. Liver Int. 2022;42:102-11.

117. Pierce TT, Ozturk A, Sherlock SP, et al. Reproducibility and repeatability of US shear-wave and transient elastography in nonalcoholic fatty liver disease. Radiology. 2024;312:e233094.

118. Zhang YN, Fowler KJ, Boehringer AS, et al. Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. Eur Radiol. 2022;32:2457-69.

119. Imajo K, Honda Y, Kobayashi T, et al. Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20:908-17.e11.

120. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150:626-37.e7.

121. Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152:598-607.e2.

122. Gidener T, Ahmed OT, Larson JJ, et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin Gastroenterol Hepatol. 2021;19:1915-24.e6.

123. Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014;60:69-77.

124. Pavlides M, Banerjee R, Tunnicliffe EM, et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int. 2017;37:1065-73.

125. Pavlides M, Banerjee R, Sellwood J, et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016;64:308-15.

126. Wang YX, Yuan J, Chu ES, et al. T1rho MR imaging is sensitive to evaluate liver fibrosis: an experimental study in a rat biliary duct ligation model. Radiology. 2011;259:712-9.

127. Allkemper T, Sagmeister F, Cicinnati V, et al. Evaluation of fibrotic liver disease with whole-liver T1ρ MR imaging: a feasibility study at 1.5 T. Radiology. 2014;271:408-15.

128. Rauscher I, Eiber M, Ganter C, et al. Evaluation of T1ρ as a potential MR biomarker for liver cirrhosis: comparison of healthy control subjects and patients with liver cirrhosis. Eur J Radiol. 2014;83:900-4.

129. Liu X, Wang Y, Xu C, Li Y, Lei J. Magnetic resonance T1ρ relaxation in patients with liver fibrosis: a systematic review and meta-analysis. Diagn Interv Radiol. 2026;32:16-24.

130. Mesropyan N, Chang J, Lutz P, et al. Clinical validation of T1ρ mapping for the assessment of hepatic fibrosis in patients with chronic liver disease. Eur Radiol. 2026;36:3983-93.

131. Qian Y, Hou J, Jiang B, et al. Characterization and correction of the effects of hepatic iron on T1ρ relaxation in the liver at 3.0T. Magn Reson Med. 2022;88:1828-39.

132. Wilczynski E, Sasson E, Eliav U, Navon G, Nevo U. Quantitative magnetization EXchange MRI measurement of liver fibrosis model in rodents. J Magn Reson Imaging. 2023;57:285-95.

133. Yarnykh VL, Tartaglione EV, Ioannou GN. Fast macromolecular proton fraction mapping of the human liver in vivo for quantitative assessment of hepatic fibrosis. NMR Biomed. 2015;28:1716-25.

134. Hou J, Wong VW, Qian Y, et al. Detecting early-stage liver fibrosis using macromolecular proton fraction mapping based on spin-lock MRI: preliminary observations. J Magn Reson Imaging. 2023;57:485-92.

135. Qian Y, Wong VW, Hou J, Jiang B, Chu WC, Chen W. Inhomogeneous liver fibrosis distribution revealed by macromolecular proton fraction quantification based on spin-lock MRI. Quant Imaging Med Surg. 2022;12:4341-5.

136. Hou J, Wong VW, Jiang B, et al. Macromolecular proton fraction mapping based on spin-lock magnetic resonance imaging. Magn Reson Med. 2020;84:3157-71.

137. Shan Q, Yu Z, Jiang B, et al. Quantitative macromolecular proton fraction imaging using pulsed spin-lock. arXiv. 2025;arXiv:2505.21853. Available from https://arxiv.org/abs/2505. 21853 [accessed 18 November 2026].

138. Malik S, Das R, Thongtan T, Thompson K, Dbouk N. AI in hepatology: revolutionizing the diagnosis and management of liver disease. J Clin Med. 2024;13:7833.

139. Zwanenburg A, Vallières M, Abdalah MA, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328-38.

140. Meng F, Wu Q, Zhang W, Hou S. Application of interpretable machine learning models based on ultrasonic radiomics for predicting the risk of fibrosis progression in diabetic patients with nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2023;16:3901-13.

141. Zhang H, Liu J, Su D, et al. Diagnostic of fatty liver using radiomics and deep learning models on non-contrast abdominal CT. PLoS One. 2025;20:e0310938.

142. Xu X, Zhu H, Li R, et al. Whole-liver histogram and texture analysis on T1 maps improves the risk stratification of advanced fibrosis in NAFLD. Eur Radiol. 2021;31:1748-59.

143. Chen ZW, Xiao HM, Ye X, et al. A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. Hepatobiliary Surg Nutr. 2022;11:212-26.

144. Tang S, Wu J, Xu S, Li Q, He J. Clinical-radiomic analysis for non-invasive prediction of liver steatosis on non-contrast CT: a pilot study. Front Genet. 2023;14:1071085.

145. Lubner MG, Malecki K, Kloke J, Ganeshan B, Pickhardt PJ. Texture analysis of the liver at MDCT for assessing hepatic fibrosis. Abdom Radiol (NY). 2017;42:2069-78.

146. Wang J, Tang S, Mao Y, et al. Radiomics analysis of contrast-enhanced CT for staging liver fibrosis: an update for image biomarker. Hepatol Int. 2022;16:627-39.

147. Dichtel LE, Tabari A, Mercaldo ND, et al. CT texture analysis in nonalcoholic fatty liver disease (NAFLD). J Clin Exp Hepatol. 2023;13:760-6.

148. Cui E, Long W, Wu J, et al. Predicting the stages of liver fibrosis with multiphase CT radiomics based on volumetric features. Abdom Radiol (NY). 2021;46:3866-76.

149. Li N, Dong X, Zhu C, et al. Association study of NAFLD with pericoronary adipose tissue and pericardial adipose tissue: diagnosis of stable CAD patients with NAFLD based on radiomic features. Nutr Metab Cardiovasc Dis. 2025;35:103678.

150. Chen ZW, Tang K, Zhao YF, et al. Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study. Int J Med Sci. 2021;18:3624-30.

151. Xia F, Wei W, Wang J, Duan Y, Wang K, Zhang C. Machine learning model for non-alcoholic steatohepatitis diagnosis based on ultrasound radiomics. BMC Med Imaging. 2024;24:221.

152. Cannella R, Borhani AA, Tublin M, Behari J, Furlan A. Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Abdom Radiol (NY). 2019;44:1816-24.

153. Jin S, Zhou T, Jin D, et al. Imaging-based fibrosis assessment and risk stratification in MASLD. Front Med. 2026;13:1880238.

154. Ma Y, Zhang C, Tian M, Hu J, Wang M, Liu S. Non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease: current status, challenges, and future directions. Diabetes Obes Metab. 2026;28:1603-13.

155. Yip TC, Lee HW, Lin H, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83:304-14.

156. Chen Y, Dong B, Jin X, et al. ; DiabetesLiver Integrated Management (DLIM) Consortium. Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes. Gut. 2026;75:576-87.Available from https://gut.bmj. com/content/75/3/576 [accessed 18 November 2026].

157. Amiama Roig C, Romero M, González N, et al. Prospective validation of the EASL-EASD algorithm for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes. Rev Esp Enferm Dig. 2026;118:317-24.

158. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362-73.

159. Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut. 2021;70:1946-53.

160. Noureddin M, Truong E, Gornbein JA, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol. 2022;76:781-7.

161. Nagaraj Sharma A, Bhagavatula H, Mapundu MT, Chimusa ER. Harnessing AI-driven approaches for detecting metabolic dysfunction-associated steatotic liver disease, assessing fibrosis, and stratifying hepatocellular carcinoma risk: a scoping review. Front Oncol. 2026;16:1803957.

162. Ye Y, Zhu W, Liu J, et al. Radiogenomics and machine learning in hepatocellular carcinoma: from foundations to clinical translation. World J Surg Oncol. 2026;24:185.

163. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223-38.

164. Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75:1476-84.

165. Boursier J, Guillaume M, Leroy V, et al. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019;71:389-96.

166. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55:403-8.

167. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65:1006-16.

168. Liang JX, Ampuero J, Niu H, et al. ; LITMUS Consortium Investigators. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023;79:592-604.

169. Ajmera V, Kim BK, Yang K, et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology. 2022;163:1079-89.e5.